Telomere shortening is associated with disease progression in chronic myeloid leukaemia (CML). To investigate the biology and regulation of telomerase in CML, we evaluated expression of the telomerase components, its regulators and several telomeric-associated proteins. Quantitative real-time-polymerase chain reaction (PCR) was used to compare gene expression in the CD34 þ /leukaemic blast cells of 22 CML patient samples to the CD34 þ cell population of healthy individuals. hTERT, the catalytic component of telomerase, was downregulated in eight of 12 chronic phase (CP) patients (P ¼ 0.0387). Furthermore, hTERT was significantly downregulated in two of three patients in accelerated phase (AP) and seven of seven patients in blast crisis (BC), P ¼ 0.0017. Expression of hTR and telomericassociated proteins TEP1, TRF1, TRF2, tankyrase and PinX1 was high in the majority of CP and AP patients. With the exceptions of TEP1 and hTR, expression of these factors was highest in CP and decreased during disease progression. Expression of c-Myc, a positive regulator of hTERT transcription, correlated with hTERT expression and decreased with disease progression, falling below control levels in BC. hTERT levels were increased in CP patients following successful treatment with imatinib, relative to untreated CP patients. We suggest that reduced hTERT expression directly causes the shortened telomeres observed in CML.
Introduction
Chronic myeloid leukaemia (CML) is a clonal disorder that originates in a pluripotent haematopoietic stem cell (HSC). 1 The Philadelphia (Ph) chromosome, or t(9;22), 2 encoding the BCR-ABL oncogenic fusion protein, is the hallmark of CML and is found in up to 95% of patients. 1 The disease inevitably progresses through a series of stages from chronic phase (CP) to accelerated phase (AP) terminating in blast crisis (BC), in which transformation to an acute leukaemia with myeloid, B-lymphoid, or occasionally T-lymphoid features occurs. [3] [4] [5] [6] The Ph chromosome is typically the only cytogenetic abnormality reported in CP patients, but cells with additional chromosomal abnormalities are commonly present at BC. 7 The availability of imatinib mesylate (Gleevec;STI571), a Bcr-Abl tyrosine kinase inhibitor, has revolutionized the treatment of CML and many newly diagnosed patients are now being successfully treated with this drug. 8 Telomeres are the termini of eukaryotic chromosomes and protect chromosomes from end to end fusions and the loss of genetic material. 9 Human telomeres consist of a tandemly repeated TTAGGG sequence. 10 Telomerase is the enzyme required for the addition of telomeric repeats to the termini of eukaryotic chromosomes. 11, 12 Human germline and stem cells express telomerase and retain the normal length of their telomeres. 13 Most somatic cells do not express telomerase and their telomeres shorten with each division. 14 Telomere repeats in such cells are successively lost with repeated cell division and this process ultimately reaches a critical point that triggers cell senescence. 15, 16 Human telomerase is a ribonucleoprotein of which the minimum components are human telomerase RNA component (hTR), 17 human telomerase catalytic subunit (hTERT) 18 and TEP1, a telomerase associated protein. 19 There is a strong correlation between the presence of hTERT mRNA and telomerase activity and it is recognized that hTERT is the rate-limiting determinant of the enzymatic activity of human telomerase. [20] [21] [22] Although various steps at post-transcriptional and post-translational level can modulate hTERT function the transcriptional control of the gene is a major contributor to the regulation of telomerase activity in human cells. 23 , 24 Nakayama et al. 20 demonstrated that ectopic hTERT expression is sufficient to confer enzymatic activity to telomerase negative cells and showed that hTERT expression is the primary determinant regulating telomerase activity. It is widely accepted that hTERT expression levels may be used as a surrogate marker for telomerase activity. [25] [26] [27] Indeed, several groups consider that the measurement of hTERT levels by quantitative real-timepolymerase chain reaction (RT-PCR) has a number of advantages over the measurement of telomerase activity by the TRAP assay. [25] [26] [27] The proto-oncogene c-Myc, a positive regulator of telomerase, is one of the major determinants of hTERT expression. 28 It acts by directly binding the hTERT promoter to induce transcription. 28 Kyo et al. 29 have shown that c-Myc and SP1 cooperatively function as the main regulators of hTERT expression. Recently, a potent inhibitor of telomerase protein activity, the TRF1-interacting protein PinX1, has been identified. 30 Telomerase activity is inhibited by direct binding of PinX1 to the catalytic subunit of telomerase, so that the RNA template cannot bind. 31 Over recent years a number of telomeric-associated proteins have been identified. The interaction between the telomericassociated proteins telomeric-repeat binding factor protein-1 (TRF1), Tin2 and tankyrase is organized to control the access of telomerase to TTAGGG telomeric repeats. A Tin2/TRF1 complex binds telomeric DNA and inhibits the access of telomerase to the telomeres to prevent the addition of more repeats. 16 Tankyrase is a TRF1-interacting factor and tankyrasemediated ADP-ribosylation of TRF1 leads to the release of TRF1 from telomeres, opening up the telomeric complex and permitting access to telomerase. [32] [33] [34] Since Tankyrase inhibits binding of TRF1 to telomeric repeats in vitro it has been suggested that tankyrase regulates TRF1 and therefore might control telomere dynamics in vivo. 34 Telomeric-repeat binding factor protein-2 (TRF2) mainly functions in telomere endprotection and is a negative regulator of telomere length. 35 Thus telomerase and tankyrase are positive regulators of telomere length, while TRF1, TRF2 and PinX1 are negative regulators. Telomere length in normal and malignant cells is regulated by a delicate balance between these factors.
Most advanced tumours express high levels of telomerase (relative to normal tissues) and the enzyme is believed to be necessary for cellular immortality and the transformation of human tumour cells. 13, 36 A reduction in telomere length has been described in a wide range of human cancers, including both solid tumours and leukaemias. [37] [38] [39] A reduction in telomere length in malignancy is frequently associated with increasing genomic instability and disease progression. 40 Reduced telomere length has been shown to be associated with disease evolution of certain haematological malignancies, including CML. 39, [41] [42] [43] We have shown that telomere length in AP and BC is reduced compared with serial samples taken at CP in patients with CML. 43 Furthermore, we have shown that telomere shortening observed at the time of diagnosis in CML significantly influences the time of progression to AP suggesting that the measurement of diagnostic telomere length may be clinically important in the selection of patients at high risk of disease transformation in CML. 44 Similarly, Brummendorf et al. 45 have shown that patients with CML, in whom the blast phase subsequently developed within 2 years, had significantly shorter telomeres than those in whom the blast phase did not develop for at least 2 years. Telomerase activity has been shown to increase in the bone marrow cells of patients with CML during disease progression. [46] [47] [48] [49] It is now recognized that telomerase-mediated telomere maintenance in malignant cells is regulated not only by hTERT expression, but also by several telomeric-associated proteins (TRF1, TRF2, TEP1 and tankyrase) that regulate the access of telomerase to the telomeres. The aim of this study was to investigate the expression levels of the components of telomerase, its regulators and several telomeric-associated proteins in the HSCs of CML patients during disease progression in order to gain insight into the biology of telomerase and its regulation in CML during disease evolution.
Patients, materials and methods

Patients
Twenty-two peripheral blood or bone marrow samples were obtained from 20 patients with CML. At the time of investigation twelve patients were in CP, three in AP, and seven in BC, Table 1 . Included in these groups are serial samples from one hTERT expression in HSCs of CML patients LJ Campbell et al patient in CP through disease progression to BC. Seven additional samples were obtained from patients in cytogenetic remission following successful treatment with imatinib. Two of these are post-treatment samples from two patients in the CP group and five are from additional CP patients in cytogenetic remission. Bone marrow samples of eight haematologically normal individuals undergoing hip replacement surgery were collected as control samples. This study was approved by the ethics committee (C00.198) and informed consent was obtained.
Samples
Bone marrow aspirates were collected in PBS supplemented with 2 mM EDTA and peripheral blood samples were collected in EDTA tubes. Mononuclear cell fractions were obtained by Histopaque density gradient centrifugation (Sigma-Aldrich, Dorset, England) and CD34 þ cells were positively selected by magnetic column selection with CD34 þ microbeads (Miltenyi Biotec Inc., Auburn, CA, USA) from controls, all CML patients in CP and AP and two of seven BC patients. The purity of the CD34 þ cells obtained from patients and controls was evaluated by flow cytometry. The purity of CD34 þ cells was always greater than 85% with most patient samples above 90%. For the majority of patients in BC (five of seven) the leukaemic blast fraction (mononuclear fraction) was separated by Histopaque density gradient centrifugation from peripheral blood samples.
Real-time quantitative polymerase chain reaction
Total RNA was extracted from patient and control samples by means of TRIzol reagent (Invitrogen-Life Technologies, Paisley, UK) according to the manufacturer's protocol. First strand cDNA was synthesized from 2 mg of total RNA using random primers with Ambion's RETROscript kit (Ambion Inc., Austin, TX, USA) after DNaseI digestion (DNA-free kit, Ambion). RNA concentration, purity and amount were determined by UV spectrophotometry.
To account for differences in input cDNA Beta-2-microglobulin (b2M) expression was examined with a predeveloped assay (Applied Biosystems, Foster City, CA, USA). hTERT and c-Myc were also quantified using predeveloped assay reagents (Applied Biosystems). For confirmation of hTERT expression data an alternative assay amplifying a different region of the gene was used (Assays on Demand, Applied Biosystems). TEP1, tankyrase and PinX1 expression were also quantified using assays on demand (Applied Biosystems). Primers and Taq-man probes for hTR and TRF2 mRNA were designed using Primer Express 2.0 software (Applied Biosystems). These primer and probe sets were synthesized by MWG-Biotech (Milton Keynes, UK). Sequences of the oligonucleotides and probe for hTR are as follows: forward primer, 5 0 -GCTGTTTTTCTCGCTGACTTTCA-3 0 , reverse primer, 5 0 -GCAGCTGACATTTTTTGTTTGCT-3 0 , and probe, 5
0 -FAM-TGCCGCCTTCCACCGTTCATTCT-TAMRA-3 0 . For TRF2: forward primer, 5 0 -ACCAGGGCCTGTGGAAAAG-3 0 , reverse primer, 5 0 -GCACCAGACAGAGTCTTGAAAGC-3 0 and probe, 5 0 -FAM-AGAACCCGCAAGGCAGCTACGGAAT-TA MRA-3 0 . Primers and probe for TRF1 are used as previously described. 50 A reverse transcriptase negative control was included for each assay to rule out any genomic DNA contamination. GAPDH (Applied Biosystems, Assays on Demand) was used as a reference gene to confirm expression data for hTERT for 18 samples for which enough material was available.
Real-time-polymerase chain reaction was performed on the ABI Prism 5700 sequence detection system (Applied Biosystems) in a 25 ml reaction volume containing 5 ml of diluted cDNA, 12.5 ml of Taqman universal PCR master mix (Applied Biosystems), and either 1.25 ml of 20 Â probe mix for pre developed assays or primers and probe to a final concentration of 300 nM for each primer and 100 nM for the probe. Thermal cycling for each assay was as follows: 2 min at 501C, 10 min at 951C, followed by 45 cycles at 951C for 15 s and 601C for 1 min. To control for intra-assay variation each assay was performed in triplicate on every patient and control sample and an average was calculated.
Splice variant polymerase chain reaction
Polymerase chain reaction to detect hTERT splice variants was carried out using a single primer set to detect all four splice variants. These PCR products were separated and quantitated on an Agilent Bioanalyser. Primers and assay conditions were as previously described by Drummond et al. 51 
Statistical analysis
Differences between disease and control groups were investigated by Mann-Whitney and Kruskal-Wallis tests, where appropriate. Correlations between expression data of related genes in patient samples were analysed by means of Spearman rank correlation test and represented as bivariate regression plots. Statistical analysis was performed using the StatView 5.0 software package (SAS Institute inc.).
Results
We have evaluated the expression levels of the components of telomerase, its regulators and several telomeric associated proteins, in the CD34 þ /blast cell populations of 22 CML patient samples as compared to the CD34 þ cell population of eight healthy individuals. Expression levels of hTR, hTERT and TEP1, (the three major subunits of telomerase), TRF1, TRF2 and tankyrase, (telomeric-associated proteins) and c-Myc and PinX1, (positive and negative regulators of telomerase, respectively), have been determined by real-time quantitative PCR assays. The expression data of each gene was normalized to the endogenous reference b2M. The normalized gene expression (Dc t ) of patients was related to the average Dc t of controls and the relative gene expression was calculated ð2
DDct Þ.
Expression of hTERT, hTR and TEP1
The expression levels of hTERT were reduced in the CD34 þ cells of patients with CP CML relative to the CD34 þ cells of normal individuals in eight of 12 patients, P ¼ 0.0387, (Table 2; Figure 1a) . hTERT was significantly downregulated in the CD34 þ /blast cell fraction in seven of seven patients with BC CML and two of three with AP CML (P ¼ 0.0017). We also used an alternative assay amplifying a different region of the hTERT transcript and results were confirmed (unpublished data). hTERT expression data was confirmed in 18 patient samples, from whom there was sufficient material, using GAPDH as a control gene. These results correlated well with the expression of hTERT using b2M as a control (Spearman r ¼ 0.855, P ¼ 0.0004). The same test was performed with GAPDH as a control for expression of the other telomerase associated genes and results showed high correlation (unpublished data). Median hTR levels were increased in the CD34 þ cells of patients in CP relative to normal controls, however, there was a wide range in the expression levels and two patients had expression levels below the range of controls (ratio 0.52 and 0.24). With the exception of one patient in BC with a marked decrease in hTR levels (ratio 0.06), levels of expression were relatively constant during disease progression (Table 2 ; Figure 1a ). Any differences in hTR gene expression levels did not reach statistical significance (P ¼ 0.1256). The expression levels of TEP1 were increased, relative to normal controls, in CP and were highest in BC CML (Table 2 ; Figure 1a ). TEP1 expression levels in BC were significantly higher than normal controls (P ¼ 0.0037).
Expression of telomerase regulators
c-Myc expression levels were high relative to controls in CP CML but, like hTERT, decreased with disease progression falling below the levels observed in normal CD34 þ cells in the majority of patients in BC (Table 2; Figure 1a) . c-Myc expression in BC was significantly lower than CP and AP (P ¼ 0.0001). Using the Spearman rank correlation test to compare hTERT and c-Myc expression in all patient samples it can be seen that c-Myc expression levels correlated positively with hTERT expression in all stages of CML (Spearman r ¼ 0.744, P ¼ 0.0007) (Figure 2a) . No correlation was observed between hTERT and the other genes investigated in this study. In serial samples available from one CML patient both hTERT and c-Myc were markedly down regulated in BC as compared to CP (Figure 1b) . PinX1 expression levels were high, relative to Abbreviations: accelerated phase (AP) n ¼ 3, blast crisis (BC) n ¼ 7, chronic phase (CP) n ¼ 12, control n ¼ 8, imatinib n ¼ 7. hTERT expression in HSCs of CML patients LJ Campbell et al controls, in the majority of patients in CP and AP (Table 2 ; Figure 1a ). Median levels of PinX1 expression decrease with disease progression. The majority of patients in BC had higher PinX1 expression levels than controls and these differences were statistically significant (P ¼ 0.0037).
Expression of telomeric-associated genes
TRF1 expression was increased in the majority of patients in CP, relative to normal controls (P ¼ 0.0015). In contrast, TRF1 expression levels were reduced, relative to normal controls, in the majority of patients in BC. Expression levels of TRF2 were increased in the CD34 þ /blast cells of the majority of CML patients in CP and AP and levels were in the range of controls in the majority of patients in BC (Table 2; Figure 1a ). Tankyrase expression levels were highest in patients in CP and AP (Table 2; Figure 1a ). Tankyrase expression in the three patient groups was significantly higher than controls, P ¼ 0.0028. Although tankyrase has no known effect on the transcription of TRF2, or vice versa, it is of interest to note that the expression levels of these two factors correlated in all stages of disease in CML patients (Spearman r ¼ 0.859, P ¼ o0.0001) (Figure 2b ).
Expression of telomerase and telomerase-associated genes in patients treated with imatinib
The expression levels of hTERT were increased in the CD34 þ cells of seven CP CML patients in remission following successful treatment with imatinib, relative to untreated CP patients and were not significantly different from normal individuals (P ¼ 0.1520). The expression levels of hTR, c-Myc, TEP1, TRF1, TRF2, PinX1 and tankyrase in these seven patients were markedly reduced as compared to untreated CP patients and furthermore the expression levels of TEP1 and TRF1 fell within the range observed in normal controls ( Table 2 ). The same pattern of gene expression was also observed in samples taken from two patients pre-and post-treatment with imatinib. The data from one of these patients is shown in Figure 1c to illustrate this point.
Splicing of hTERT RNA
The þ a þ b transcript is full length functional hTERT. Àa þ b is a dominant negative inhibitor of hTERT activity while the þ aÀb and ÀaÀb transcripts are inactive truncated proteins. 51, 52 We have observed a shift in the splicing patterns of hTERT in CML. The proportion of þ aÀb is decreased in CML patients in all stages of disease and the proportion of þ a þ b transcripts is increased, however these changes do not reach statistical significance (Figure 3 ). The levels of Àa þ b and ÀaÀb transcripts were not significantly different from levels in normal controls.
Discussion
Normal haematopoietic CD34
þ stem cells, in common with all stem cells of renewal tissues, show a low level of telomerase activity. 53 We have evaluated the gene expression levels of hTERT, the key determinant of the enzymatic activity of human telomerase, [20] [21] [22] in the purified CD34 þ /blast cell populations of CML patients relative to the CD34 þ cell population of a group of healthy individuals and have observed that hTERT is downregulated in the CD34 þ cells of the majority of CML patients studied in all phases of disease. The gene expression levels of hTERT progressively decrease with disease evolution (Figure 1a) .
The major finding that hTERT is downregulated in the CD34 hTERT expression in HSCs of CML patients LJ Campbell et al increase in telomerase protein activity with disease progression in CML and that telomerase activity is higher in BC than CP. [47] [48] [49] 54, 55 In these earlier studies, telomerase protein activity, not hTERT levels, were measured in unfractionated bone marrow samples, bone marrow mononuclear cells or peripheral blood obtained from CML patients in CP, AP and BC. Ohyashiki et al. 47 for example, showed that the bone marrow (mononuclear fraction) or peripheral blood samples of all 33 CP patients studied had detectable telomerase activity above background (normal peripheral blood cells) and noted a significant increase in telomerase activity in the bone marrow (mononuclear fraction) or peripheral blood samples of 21 BC patients, relative to both CP patients and control normal peripheral blood cells. Clearly, CML patients with BC have a higher percentage of blast cells than patients in CP. In the current study we have compared hTERT expression in normal CD34 þ cells with CML CD34 þ /blast cells. Therefore, this may explain the discrepancy in the findings between our study and these earlier reports. The differences in telomerase activity observed in previous studies might simply be a reflection of the differences in the number of immature cells present in the samples studied, that is, the mononuclear cell fraction in BC CML will contain higher numbers of blast cells (expressing telomerase) than the mononuclear fraction from normal or CP CML, which would give a result of higher telomerase activity. This is consistent with data from Li et al. 56 showing a linear correlation between telomerase activity and the logarithm of bone marrow blast percentages in CML.
In support of our findings Drummond et al., 51 in a recent study of CP CML, showed that hTERT expression in CD34 þ cells of CP patients is not significantly different from CD34 þ cells from controls. This group also showed that telomerase activity, when a correction for the decreased number of cells in G 0 in CP CML is taken into account, is not significantly increased in CML when compared with controls. 51 This suggests that small differences in telomerase activity between these samples are primarily a reflection of cell cycle status, and may not reflect a genuine cell-to-cell increase in telomerase activity in CML.
Interestingly, it has been shown that antisense inhibition of Bcr-Abl/c-Abl enhances hTERT levels. 57 We suggest that the presence of the Bcr-Abl fusion product in CML may contribute to the downregulation of hTERT observed in the CD34 þ /blast cells of CML patients in this study.
hTR, is commonly expressed in both malignant and normal cells 58 and several studies have shown that hTR is upregulated during tumorigenesis. 58, 59 Expression of hTR has previously been determined in many cancers and it generally does not correlate with hTERT expression levels. [60] [61] [62] Unlike hTERT, the expression of hTR does not predict the presence or amount of telomerase activity. 58, 63 We have shown that hTR levels, in general, were increased in the CD34 þ cells from the majority of CML patients in all phases (however, two CP patients have hTR expression levels below the range of normal controls). In the study by Drummond et al.,
51 a significant decrease in the expression of hTR was noted in some CP CML patients. In the majority of patients in our study the changes in expression levels of hTR did not correlate with the changes in expression levels observed for hTERT. Similar observations have been made in many other malignancies including AML and thyroid cancer. 60, 61 c-Myc positively regulates telomerase and a significant association between c-Myc over-expression and elevated hTERT expression has been demonstrated in several cancers. 25, 64, 65 We have shown that c-Myc expression levels were high in most patients in CP and decreased with disease progression falling below the levels observed in controls in the majority of BC patients. The expression levels of hTERT and c-Myc showed a significant correlation in all stages of CML (Figure 2b, Figure 1b) . Treatment of leukaemia cells with anti-sense oligonucleotides targeted against c-Myc mRNA leads to inhibition of telomerase activity. 66 We suggest that the downregulation of hTERT observed in the CD34 þ /blast cells obtained from BC CML patients may, at least in part, be a direct consequence of the reduced levels of c-Myc in these cells.
PinX1 and the telomeric associated proteins TRF1, TRF2 and tankyrase showed increased expression levels in the CD34 þ / blast cells of the majority of CML patients in CP and AP. TRF1 inhibits the action of telomerase at the telomeric region 67 and the increased expression levels of TRF1 in CP and AP may contribute to the telomere shortening observed in CML. High expression levels of TRF2 in human primary cells has been shown to prevent or delay the signalling of critically shortened telomeres to induce senescence. 68 High levels of tankyrase in telomerase-positive human cells results in elongation of telomeres. 34 A correlation was noted in the expression levels of the telomere binding proteins TRF2 and tankyrase (Figure 2b ) and we speculate that the parallel upregulation of these genes could contribute to telomere maintenance in CML.
The expression levels of hTERT were increased in the CD34 þ cells of the seven CP patients in remission following successful treatment with imatinib as compared to untreated CP patients. Interestingly, the extension of telomeres in CML patients after long-term treatment with imatinib in CP CML has been reported. 69 The expression levels of hTR, c-Myc, TEP1, TRF1, TRF2, PinX1 and tankyrase in the seven patients were markedly reduced as compared to untreated CP CML patients and furthermore the expression levels of TEP1 and TRF1 fell within the range observed in normal controls, reflecting a restoration of haematopoiesis towards normality (Table 2) . Such changes were also observed in samples taken from two patients pre-and posttreatment with imatinib ( Figure 1c) . By measuring gene expression levels in serial samples from these patients we have observed the gradual return towards normal haematopoiesis and the concomitant normalisation of the telomerase related gene expression levels. Expression of the other telomerase associated genes in patients treated with imatinib did not always fall within the range of controls but, in general, was not significantly different from controls. This is in agreement with a study by Neumann et al. 70 showing that most genes have unchanged expression in patients in cytogenetic remission after treatment when compared to normals. It is possible that with longer periods of treatment expression of all genes investigated in this study will fall within the normal range in these patients. The patients in the present study were treated for 3 months, while in the investigation by Neumann et al. patients had undergone treatment for at least eleven months.
Alternative splicing of hTERT transcripts represents an additional level of gene regulation. We sought to investigate the proportions of the four alternative splice variants of hTERT in CML. The relative proportion of full length active þ a þ b transcripts is increased in CML patients while the proportion of inactive þ aÀb is decreased, although this does not reach statistical significance. Therefore, we can speculate that while the overall expression levels of hTERT are decreased in the CD34 þ cells of the CML patients studied a shift in splicing patterns could allow a higher proportion of þ a þ b transcripts to be active and therefore maintain telomere length above the critical level. Drummond et al. 51 similarly noted an increase in the levels of the þ a þ b transcripts at the expense of the þ aÀb in CP CML as compared to normal controls.
The major finding of this study is that hTERT is downregulated in the CD34 þ cells of CML patients in all stages of the disease. We suggest that the downregulation of hTERT observed in the CD34 þ /blast cells of CML patients may be the consequence of the downregulation of c-Myc and the presence of the Bcr-Abl fusion product in these cells. Low levels of hTERT could carry out minimal telomere maintenance in these cells and we speculate that the upregulation of tankyrase (positive regulator of telomere length) and TRF2 (protects critically shortened telomeres) may contribute to telomere maintenance in CML.
A marked reduction in telomere length has been reported in many human tumours together with high levels of telomerase activity. This apparent paradox is frequently explained by such tumours having multiplied to such an extent that activation of telomerase is essential for survival, that is, it is required to stabilize telomere length and to halt the loss of further DNA. Counter et al. 71 hypothesized that telomerase activation in immortal cells was required for telomere stabilization and Zhu et al. 72 provided evidence that virus-transformed human fibroblasts with ectopic hTERT expression had an extended lifespan but shortened telomeres. However, while is accepted that most tumours express hTERT and are telomerase positive, it is not usually clear whether the observable hTERT expression is due to their origin from telomerase positive stem cells or due to reactivation of the gene during tumorigenesis. Such studies, which have compared hTERT or telomerase activity in tumour cells with corresponding normal tissues, and not the normal stem cells of origin, have given rise to the observation that tumour cells have increased levels of telomerase. However, in solid tumours it is not possible to compare tumour cells with their corresponding stem cells as it is for leukaemia cells with CD34 þ stem cells. Interestingly, two recent reports challenge the conventional view that hTERT is repressed in somatic cells but activated in neoplastic cells. Liu et al. 73 have shown that hTERT is highly expressed in normal breast ductal-lobular units and downregulated in ductal carcinoma in situ. Klapper et al. 74 show that telomerase activity and hTERT levels in non-Hodgkin lymphomas are indistinguishable from levels in reactive lymph nodes.
Our study clearly demonstrates that the CD34 þ /blast cells of patients with CML possess lower hTERT expression levels than CD34 þ /blast cells from normal individuals. Like other stem cells the telomeres of normal CD34 þ cells are maintained by low levels of telomerase and show only gradual telomere shortening with ageing and rapid cycling. Telomerase activity ensures that the stem cell compartment will be able to respond adequately to large expansion demands and, while the telomeres still gradually shorten, the time to critically shortened length is delayed by telomerase. In CML the turnover of all types of Ph þ stem and progenitor cells is known to be increased and several studies suggest that telomere length measurements may be a useful indication of stem cell turnover in vitro and in vivo. 45 We suggest that the reduced (and presumably inadequate) expression level of hTERT in CML CD34
þ /blast cells is the direct cause of the shortened telomeres frequently observed in CML patients. This phenomenon accelerates during disease progression and may correlate with the increasing genomic instability exhibited by CML with disease progression. It is interesting to note that mice deficient in telomerase that are maintained over many generations show increased chromosomal instability together with a marked increase in the incidence of cancer. 75 The data presented here challenge the widely accepted view that hTERT expression is always increased in tumorigenesis and support a mechanistic link between CML stem cell turnover, telomere shortening and genetic instability, disease evolution and diminished hTERT expression.
